Stochastic Liquidity as a Proxy for Nonlinear Price Impact
Operations Research · 2024-03 · 72 (2) · 444-458
DOI: 10.1287/opre.2022.0627 ↗Kurz gefasst
Fachartikel in der Zeitschrift Operations Research, 2024-03. Verfasst von Johannes Muhle-Karbe und 2 weiteren Autor:innen. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben.
Abstract (Originalsprache)
For the “In This Issue” column: Trading costs play a central role in designing and implementing quantitative trading strategies. To quantify trading costs, optimal execution and trading algorithms rely on price impact models, such as the propagator model. Empirically, price impact is concave in trade sizes, leading to nonlinear models for which optimization problems are intractable and even qualitative properties, such as price manipulation, are poorly understood. This paper shows that, in the diffusion limit of small and frequent orders, the nonlinear model converges to a tractable linear model. In this high-frequency limit, a stochastic liquidity parameter approximates the original impact function’s nonlinearity. This allows us to derive simple formulas for optimal trading strategies and sharp conditions on market volumes to rule out price manipulation. A detailed empirical study using high-frequency limit-order data illustrates the practical performance of the theoretical results.
Zitieren
APA
Muhle-Karbe, J., Wang, Z., & Webster, K. (2024). Stochastic Liquidity as a Proxy for Nonlinear Price Impact. Operations Research, 72(2), 444-458. https://doi.org/10.1287/opre.2022.0627
Vancouver
Muhle-Karbe J, Wang Z, Webster K. Stochastic Liquidity as a Proxy for Nonlinear Price Impact. Operations Research. 2024;72(2):444-458. doi:10.1287/opre.2022.0627
BibTeX
@article{MuhleKarbe2024,
author = {Muhle-Karbe, Johannes and Wang, Zexin and Webster, Kevin},
title = {Stochastic Liquidity as a Proxy for Nonlinear Price Impact},
journal = {Operations Research},
year = {2024},
volume = {72},
number = {2},
pages = {444--458},
doi = {10.1287/opre.2022.0627}
}
EUVIMED